SAN DIEGO—High-dose rather than conventional-dose ergocalciferol may be more effective at increasing 25-hydroxyvitamin D levels and decreasing parathyroid hormone (PTH) levels in patients with chronic kidney disease (CKD), researchers concluded in a presentation at Kidney Week.
Bancha Satirapoj, MD, and colleagues at Phramongkutklao Hospital in Bangkok, Thailand, studied 63 CKD patients with vitamin D insufficiency (serum 25-hydroxyvitamin D [25-OHD] levels below 30 ng/mL). The researchers randomly assigned patients into 2 groups: a conventional treatment group treated with oral ergocalciferol as recommended by Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines, and a high-dose oral ergocalciferol group treated with double the recommended dosage of ergocalciferol.
From baseline to 12 weeks, the mean 25-OHD level increased significantly in both groups: from 18.98 to 27.95 ng/mL in the conventional-treatment group and from 18.15 to 32.08 ng/mL in the high-dose group. The increase in 25-OHD levels was significantly greater in the high-dose than conventional-treatment arm (13.64 vs. 8.52 ng/mL). The high-dose group also experienced significantly greater decreases in serum PTH level (-16.75 vs. -0.25 pg/mL). The groups did not differ significantly with respect to serum calcium and phosphate. The researchers observed no adverse effect associated with treatment.